Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology announced that The New England Journal of Medicine published a peer-reviewed letter highlighting 14-month data for UP421, showing that hypoimmune-modified islet cells survived and produced insulin without immunosuppression. The study demonstrated safety and durable cell function via C-peptide production, though the low-dose trial was not designed to show improved glycemia.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.